Carbohydrate-Deficient Glycoprotein Syndrome Type IIo

Carbohydrate-deficient glycoprotein syndrome type IIo is a very rare, inherited (genetic) disorder where the body cannot “finish” making and correctly processing sugar chains (glycans) that normally attach to many proteins. These sugar chains help proteins fold, travel, and work properly, so when glycosylation is faulty, many organs can be affected—especially the liver, brain/nerves, growth, and development. Today, this condition is usually described as CCDC115-CDG (also called CDG2O / CDG-IIo). Genetic Diseases Info Center+2Orpha+2

How CDG-IIo happens

Most reported CDG-IIo (CCDC115-CDG) cases happen because of disease-causing changes (variants) in the CCDC115 gene. This gene helps the Golgi apparatus (a “packing and finishing” area inside cells) keep the right chemical environment so proteins can receive the right sugar chains. When CCDC115 does not work well, the Golgi cannot glycosylate proteins normally, and this can lead to progressive liver disease, low muscle tone, developmental delay, and sometimes seizures. Cell+2Genetic Diseases Info Center+2

In CDG-IIo, the most known genetic cause is biallelic (two-copy) mutations in the CCDC115 gene. Studies describe a pattern of abnormal N-glycosylation and mucin-type O-glycosylation on blood proteins, and many patients show liver disease, abnormal copper handling (“Wilson-like” findings), and neurologic problems such as low muscle tone and developmental delay. PubMed+2SpringerLink+2

Another names

You may see the same condition written with different names, because older naming used “carbohydrate-deficient glycoprotein syndrome,” while newer naming often uses the gene name. Common names include Congenital disorder of glycosylation, type IIo, CDG-IIo, CDG2O, and CCDC115-CDG. PubMed+1

CCDC115 is also described as related to V-ATPase assembly / Golgi homeostasis, so some papers discuss CDG-IIo inside a broader group of V-ATPase–assembly-related liver glycosylation disorders. PubMed+2eLife+2

Types

Below are “types” shown in a practical way (because CDG naming is used in more than one system). NCBI+1

1. Old biochemical grouping: CDG-I vs CDG-II
   CDG-I usually means the problem is in building or transferring the glycan in the ER, while CDG-II usually means the problem is in processing/finishing glycans (often in the Golgi). CDG-IIo belongs to the CDG-II side. NCBI+1

2. Gene-based naming (modern): “GENE-CDG”
   Many experts now name CDGs by the gene (example: CCDC115-CDG). This is clearer because there are many CDG subtypes. Wikipedia+1

3. Clinical? subgroup sometimes discussed: V-ATPase assembly / Golgi pH homeostasis–related CDG
   Some articles group CCDC115-CDG with other disorders that disturb Golgi/vesicle trafficking and/or lumen acidification (pH), because these can produce similar liver-heavy phenotypes. PubMed+2eLife+2

Causes

Because CDG-IIo is a genetic disorder, the “cause” is mainly the gene change. To match your request for 20 items, this section explains 20 cause-steps (what starts it + what goes wrong in the body). PubMed+1

1. Two faulty copies of CCDC115 (biallelic mutation)
   Most confirmed CDG-IIo cases happen when a person inherits two disease-causing variants in CCDC115, which reduces or disrupts normal CCDC115 function. PubMed+1

2. Autosomal recessive inheritance
   CDG-IIo is typically autosomal recessive, meaning parents are often healthy carriers and the child receives one changed copy from each parent. MalaCards+1

3. Carrier parents (both parents carry one altered copy)
   A child is at risk when both parents carry a CCDC115 variant, even though they usually have no symptoms themselves. MalaCards+1

4. Consanguinity can raise the chance (in some families/populations)
   In autosomal recessive diseases, related parents can increase the chance that both carry the same rare variant. This is a general genetic risk pattern for recessive disorders. NCBI

5. Loss of normal Golgi “homeostasis” (Golgi does not work normally)
   Research describes CDG-IIo as a disorder of Golgi homeostasis, meaning the Golgi’s internal environment and trafficking are disturbed. PubMed

6. Abnormal protein glycosylation (sugar chains on proteins become abnormal)
   When Golgi processing fails, many proteins leave the liver and other tissues with incorrect glycan structures, which can change how they work in the body. NCBI+1

7. Combined N-glycosylation and mucin-type O-glycosylation problems
   In CDG-IIo, studies found abnormal N-glycosylation and also abnormal mucin-type O-glycosylation on serum proteins. PubMed+1

8. Hyposialylation (loss/reduction of sialic acid on glycans)
   A common biochemical theme in Golgi-processing CDGs is reduced “capping” of glycans with sialic acid, which changes blood protein patterns seen in testing. NCBI+2PubMed+2

9. Reduced galactose residues on glycans (another “finishing” step fails)
   The CDG-IIo paper describes glycan profiles showing loss of sialic acid and galactose, which fits a Golgi processing problem. PubMed

10. Disrupted trafficking in the ER-Golgi region
    CCDC115 was reported to localize mainly to the ERGIC and COPI vesicles, suggesting a role in Golgi/vesicle trafficking—important for correct glycosylation enzyme placement. PubMed

11. Functional link to V-ATPase assembly factors (cell acidification machinery)
    CCDC115 has been discussed as related to V-ATPase assembly in human cells (based on homology to yeast factors and human data), which can affect organelle pH and Golgi function. PubMed+2eLife+2

12. Golgi lumen pH disturbance can weaken glycosylation enzymes
    Many Golgi glycosylation enzymes work best at the right pH; V-ATPase–related pathways help regulate this, so disruption can indirectly impair glycan processing. PubMed+1

13. Mis-glycosylated liver proteins (secreted proteins become “wrongly built”)
    The liver makes many blood proteins (including clotting proteins). When glycosylation is abnormal, the liver’s exported proteins can function poorly. NCBI+1

14. Coagulation abnormalities can arise from abnormal glycoproteins
    CDG disorders often include coagulation defects because clotting proteins are glycoproteins; abnormal glycosylation can disturb their stability and function. NCBI

15. Abnormal lipid handling (dyslipidemia such as high cholesterol?)
    Patients with CDG-IIo were reported with elevated cholesterol, which may relate to liver dysfunction and broad glycoprotein/lipoprotein processing problems. PubMed+1

16. Abnormal copper metabolism (Wilson-like pattern in some patients)
    Reports describe CDG-IIo patients with abnormal copper metabolism and liver findings that can look like Wilson disease. PubMed+1

17. Progressive liver injury (can move from enzyme elevation to cirrhosis?/failure)
    In CDG-IIo, liver disease can be severe?, including early cirrhosis and even liver failure in some cases. PubMed+1

18. Neurologic involvement from widespread glycoprotein problems
    Glycosylation is important for brain development and nerve function; CDG disorders commonly affect the nervous system, causing hypotonia and developmental delay. NCBI+1

19. Cell stress from abnormal protein processing
    When cells make many incorrectly processed proteins, they can show signs of internal stress (for example, altered organelle structure reported in functional studies). PubMed

20. Overall multisystem effect because glycosylation is used everywhere
    Glycosylation is a basic “body-wide” process, so a single Golgi processing defect can affect many organs at the same time, not just one. NCBI+1

Symptoms

Symptoms vary from person to person. The items below are common or well-described in published cases and CDG reviews. PubMed+2SpringerLink+2

1. Low muscle tone (hypotonia)
   Babies may feel “floppy,” have weak head control, and struggle with posture because the nervous system and muscles are affected. NCBI+1

2. Developmental delay
   Children may reach milestones late (sitting, walking, talking) because glycosylation problems can affect brain development and function. NCBI+1

3. Global learning / intellectual disability?
   Some patients have long-term learning difficulties, which fits the broader CDG pattern of neurodevelopmental involvement. NCBI+1

4. Liver enlargement (hepatomegaly?)
   The liver can become enlarged, sometimes together with spleen? enlargement, due to ongoing liver injury and storage-like changes described in CDG-IIo. PubMed+1

5. Spleen enlargement (splenomegaly)
   Hepatosplenomegaly (liver + spleen enlargement) has been described, sometimes looking like a “storage disease” pattern. PubMed

6. High liver enzymes (elevated aminotransferases)
   Blood tests may show high AST/ALT, reflecting liver cell stress or damage, and this is described in CDG-IIo reports. PubMed+1

7. Neonatal jaundice? (yellow skin/eyes in early life)
   Some CDG-IIo patients have jaundice? early in life, which can signal cholestasis or liver dysfunction. SpringerLink

8. Early liver scarring (fibrosis?/cirrhosis)
   Severe cases can develop early cirrhosis, which is one reason CDG-IIo may progress to liver failure. SpringerLink

9. Progressive liver failure (in severe cases)
   Some individuals have progressed to liver failure; at least two deaths from liver failure were noted in the key CDG-IIo report. PubMed+1

10. Abnormal copper metabolism (Wilson-like features)
    Doctors may notice copper-related test abnormalities that can look similar to Wilson disease, even though the root cause is glycosylation. PubMed+1

11. High cholesterol (hypercholesterolemia)
    Elevated cholesterol has been reported in affected individuals, likely linked to liver involvement and disturbed Golgi processing. PubMed+1

12. Very high alkaline phosphatase (often bone-derived)
    The CDG-IIo paper reports highly elevated alkaline phosphatase (bone-derived), which can be a clue in work-up. PubMed

13. Feeding problems / poor growth (failure to thrive?)
    Many CDG conditions cause feeding difficulty and poor growth because multiple organ systems are involved, including liver and neurologic control of feeding. NCBI+1

14. Bleeding tendency or abnormal clotting tests
    Because the liver makes clotting proteins and glycosylation affects them, CDG patients can show abnormal coagulation tests and bleeding risk. NCBI+1

15. Seizures (in some CDG patients)
    Not every CDG-IIo patient has seizures, but seizures are common across many CDG types, so clinicians often screen for them in suspected CDG. Frontiers+1

Diagnostic tests

These are the most used tests to suspect, screen, and confirm CDG-IIo. Final diagnosis? usually needs genetic testing plus glycosylation evidence. Frontiers+2PubMed+2

Physical exam 

1. General growth exam (weight/length/head circumference)
   Helps detect poor growth or micro/macrocephaly patterns that can appear in multisystem genetic disorders like CDG. NCBI

2. Neurologic exam for tone and reflexes
   A clinician checks hypotonia, reflex changes, and movement quality, which are common clinical clues in CDG. NCBI+1

3. Abdominal exam for enlarged liver/spleen
   Feeling the abdomen? can detect hepatosplenomegaly, a key sign described in CDG-IIo. PubMed+1

4. Skin/eye exam for jaundice
   Looking for yellow discoloration is a simple bedside clue for liver dysfunction or cholestasis. SpringerLink

Manual tests 

5. Developmental screening? (age-appropriate milestone testing)
   Structured milestone checks identify delays early and guide referral for genetics/metabolic testing when multisystem signs exist. Frontiers+1

6. Feeding/swallow assessment? (clinical bedside assessment)
   A clinician or therapist checks suck–swallow coordination and aspiration risk, which can be affected by hypotonia and neurologic issues. NCBI+1

7. Motor function assessment (physical therapy? evaluation)
   Manual strength, posture, and movement assessment helps quantify hypotonia and motor delay typical of CDG presentations. NCBI

8. Liver disease clinical scoring / signs review (manual clinical assessment?)
   Doctors look for bruising?, swelling?, fatigue?, itching?, stool/urine color changes—signs that support significant liver involvement in CDG-IIo. SpringerLink

Lab and pathological tests 

9. Serum transferrin isoelectric focusing (Tf IEF)
   This is a key screening test for CDG. A type II pattern suggests a processing defect after glycan transfer, often in the Golgi. Frontiers+1

10. Mass spectrometry (MS?) of transferrin or plasma N-glycans
    MS gives more detailed and sensitive information than IEF and can show missing terminal sugars (like sialic acid/galactose). NCBI+2Frontiers+2

11. Apolipoprotein C-III isofocusing (ApoC-III IEF)
    After a CDG-II pattern, ApoC-III testing helps detect mucin-type O-glycosylation problems and supports a combined N+O defect. Frontiers+1

12. Genetic testing: targeted CDG gene panel / exome sequencing
    Because Tf IEF can be normal in some CDGs, gene testing is often needed to confirm the diagnosis; for CDG-IIo the key gene is CCDC115. Frontiers+1

13. Liver enzymes (ALT, AST, GGT, bilirubin?)
    These tests measure liver injury and cholestasis and are important because CDG-IIo is strongly linked with liver disease. SpringerLink+1

14. Coagulation tests (PT/INR, aPTT, specific factors if needed)
    CDG can cause coagulation problems because glycosylation affects clotting proteins; abnormal results support systemic liver/glycoprotein involvement. NCBI+1

15. Lipid profile (total cholesterol, LDL, HDL, triglycerides)
    High cholesterol and other lipid abnormalities can appear in CDG-IIo and related liver-heavy CDGs. PubMed+1

16. Copper studies (ceruloplasmin, serum/urine copper; liver copper if biopsied)
    Because CDG-IIo can look “Wilson-like,” copper work-up helps rule out classic Wilson disease and recognize the CDG pattern. SpringerLink+1

17. Liver biopsy pathology (only when clinically needed)
    A biopsy can show fibrosis/cirrhosis and measure liver copper; it is not always required, but it can help when diagnosis is unclear. SpringerLink

Electrodiagnostic tests

18. EEG (electroencephalogram)
    EEG is used if seizures are suspected; seizures are common across CDG conditions, so EEG helps assess brain electrical activity. Frontiers

19. EMG / nerve conduction studies (when neuropathy/myopathy is suspected)
    These tests measure nerve and muscle electrical function and can help separate central hypotonia from peripheral nerve/muscle disease. NCBI+1

Imaging tests

20. Abdominal ultrasound (liver/spleen size and structure)
    Ultrasound can document hepatosplenomegaly, fatty change, nodularity, or signs of chronic liver disease, supporting the clinical picture of CDG-IIo. SpringerLink

Non-pharmacological treatments (therapies and others)

1. Care coordination (metabolic/genetics + liver + neurology team). Purpose: one plan for many organs. Mechanism: regular monitoring (growth, liver labs, development) catches problems early and prevents crises. Genetic Diseases Info Center+1

2. Early intervention program. Purpose: improve learning and daily skills. Mechanism: frequent structured practice helps the brain build stronger pathways during early childhood. Genetic Diseases Info Center+1

3. Physiotherapy (PT). Purpose: strength, balance, and mobility. Mechanism: guided movement reduces stiffness, supports posture, and prevents contractures over time. ScienceOpen+1

4. Occupational therapy (OT). Purpose: daily activities (feeding, dressing, hand use). Mechanism: adaptive techniques and tools reduce effort and improve independence. ScienceOpen+1

5. Speech and language therapy. Purpose: communication and swallowing support. Mechanism: exercises and strategies improve safe swallowing and help language development. ScienceOpen+1

6. Feeding therapy + texture planning. Purpose: safer eating and better calories. Mechanism: matching textures to swallow ability reduces choking/aspiration risk. MDPI+1

7. High-calorie nutrition plan (dietitian-guided). Purpose: improve growth/energy. Mechanism: concentrated calories and protein help meet needs even with low appetite or fatigue. MDPI+1

8. Swallow study and aspiration prevention plan. Purpose: reduce pneumonia risk. Mechanism: testing identifies unsafe swallowing patterns so caregivers can change feeding method/positioning. MDPI+1

9. Positioning during and after feeds. Purpose: reduce reflux and choking. Mechanism: upright posture helps gravity keep food in the stomach and supports safer swallowing. MDPI+1

10. Sleep routine + environment. Purpose: better sleep and behavior. Mechanism: consistent timing and reduced stimulation support normal sleep signals and reduce nighttime awakenings. ScienceOpen+1

11. Seizure safety plan (school + home). Purpose: prevent injuries and delays in care. Mechanism: caregivers learn what to do during seizures and when to call emergency services. Genetic Diseases Info Center+1

12. Developmental and autism-style supports when needed. Purpose: social and learning progress. Mechanism: structured teaching and predictable routines lower stress and improve skill building. Genetic Diseases Info Center+1

13. Respiratory physiotherapy (if weak cough). Purpose: clear mucus and reduce infections. Mechanism: airway-clearance techniques help move secretions out of the lungs. MDPI+1

14. Regular liver follow-up (hepatology). Purpose: detect progression early. Mechanism: tracking enzymes, clotting tests, albumin, and imaging guides timely nutrition and transplant discussions. Frontiers+2SpringerLink+2

15. Vaccination plan (including extra protection when advised). Purpose: prevent severe infections. Mechanism: vaccines train the immune system safely, reducing hospitalization risk. Genetic Diseases Info Center+1

16. Infection prevention habits at home. Purpose: fewer infections. Mechanism: hand hygiene, safe food/water, and avoiding sick contacts reduce germ exposure. Genetic Diseases Info Center+1

17. Vision/hearing screening and early correction. Purpose: better development. Mechanism: glasses/hearing aids remove barriers to learning and communication. Genetic Diseases Info Center+1

18. Orthotics and mobility aids. Purpose: safer walking/sitting. Mechanism: braces/support devices align joints and reduce falls and deformities. ScienceOpen+1

19. Caregiver training (feeding, seizures, emergency plan). Purpose: safer daily life. Mechanism: practical training reduces delays and mistakes during high-risk moments. ScienceOpen+1

20. Genetic counseling for the family. Purpose: understand recurrence risk and testing options. Mechanism: explains inheritance, carrier testing, and prenatal/preimplantation choices. Genetic Diseases Info Center+1

Drug treatments

Safety note: Doses for CDG-IIo are individualized by clinicians (age, weight, organ function, other drugs). Use only under a licensed prescriber and follow the FDA label and local guidelines. ScienceOpen+1

1. Levetiracetam (Keppra) for seizures. Class: antiepileptic. Typical timing: twice daily. Purpose: reduce seizure frequency. Mechanism: stabilizes nerve signaling (exact mechanism not fully known). Side effects: sleepiness, mood/behavior changes. FDA Access Data

2. Valproic acid (Depakene/Depakote family) for seizures. Class: antiepileptic. Timing: usually 2–3 times/day. Purpose: seizure control. Mechanism: increases inhibitory signaling (GABA) and affects ion channels. Side effects: liver risk, weight gain, tremor (needs careful liver monitoring). FDA Access Data+1

3. Lamotrigine (Lamictal) for seizures. Class: antiepileptic. Timing: daily or twice daily with slow titration. Purpose: seizure prevention. Mechanism: sodium-channel effects that reduce over-firing neurons. Side effects: rash (can be serious), dizziness. FDA Access Data

4. Topiramate (Topamax) for certain seizure types. Class: antiepileptic. Timing: often twice daily. Purpose: reduce seizures. Mechanism: multiple actions on ion channels and neurotransmitters. Side effects: appetite loss, slowed thinking, kidney stones risk. FDA Access Data

5. Clobazam (Onfi) for difficult seizures (specialist-guided). Class: benzodiazepine. Timing: once/twice daily. Purpose: seizure reduction. Mechanism: increases GABA-A calming signals. Side effects: sleepiness, dependence, breathing risk with other sedatives. FDA Access Data+1

6. Clonazepam (Klonopin) for seizures or severe myoclonus. Class: benzodiazepine. Timing: 2–3 times/day. Purpose: calm abnormal electrical activity. Mechanism: boosts GABA-A inhibition. Side effects: sedation, tolerance, withdrawal if stopped suddenly. FDA Access Data+1

7. Diazepam rectal gel (Diastat) for seizure clusters/emergencies. Class: benzodiazepine rescue med. Timing: “as directed” for clusters. Purpose: stop prolonged/cluster seizures. Mechanism: rapid GABA-A enhancement. Side effects: sleepiness, slowed breathing (emergency plan needed). FDA Access Data+1

8. Baclofen for spasticity (muscle tightness). Class: antispastic muscle relaxant. Timing: multiple times/day. Purpose: reduce stiffness and pain. Mechanism: GABA-B receptor activity in spinal cord. Side effects: drowsiness, weakness. FDA Access Data

9. Omeprazole (Prilosec) for reflux/GERD. Class: proton pump inhibitor. Timing: once daily (sometimes twice). Purpose: protect esophagus and reduce pain/vomiting. Mechanism: lowers stomach acid production. Side effects: diarrhea, low magnesium with long use (monitor if prolonged). FDA Access Data+1

10. Famotidine (Pepcid) for reflux/acid symptoms. Class: H2 blocker. Timing: once or twice daily. Purpose: reduce acid and discomfort. Mechanism: blocks histamine-2 receptors in stomach. Side effects: headache, constipation/diarrhea. FDA Access Data+1

11. Ursodiol (ursodeoxycholic acid) for cholestasis-type liver/bile flow problems (when appropriate). Class: bile acid. Timing: divided doses with food. Purpose: improve bile flow and reduce bile toxicity. Mechanism: changes bile composition and protects bile ducts. Side effects: diarrhea. FDA Access Data+1

12. Phytonadione (Vitamin K1) for bleeding tendency due to low vitamin K–dependent clotting factors (only if indicated by tests). Class: vitamin/coagulation support. Timing: as prescribed. Purpose: improve clotting. Mechanism: helps liver make clotting factors. Side effects: rare reactions; dosing must be supervised. FDA Access Data+1

13. Ondansetron (Zofran) for nausea/vomiting (short-term when needed). Class: 5-HT3 antiemetic. Timing: as needed. Purpose: reduce vomiting and dehydration. Mechanism: blocks serotonin receptors involved in vomiting reflex. Side effects: constipation, QT-risk in susceptible patients. FDA Access Data+1

14. Acetaminophen (paracetamol; IV example label) for fever/pain (clinician-guided, liver-safe dosing is critical in liver disease). Class: analgesic/antipyretic. Timing: every several hours as directed. Purpose: comfort and fever control. Mechanism: central pain/fever pathway effects. Side effects: liver toxicity if overdosed. FDA Access Data+1

15. Ibuprofen (IV example label) for pain/inflammation when appropriate. Class: NSAID. Timing: as directed. Purpose: pain/fever. Mechanism: COX inhibition lowers inflammatory prostaglandins. Side effects: stomach bleeding, kidney risk—extra caution in fragile patients. FDA Access Data+1

16. Amoxicillin/clavulanate (Augmentin) for bacterial infections when prescribed. Class: penicillin antibiotic + beta-lactamase inhibitor. Timing: usually 2–3 times/day. Purpose: treat susceptible infections. Mechanism: blocks bacterial cell wall; clavulanate protects amoxicillin. Side effects: diarrhea, rash; allergy risk. FDA Access Data

17. Ceftriaxone (Rocephin/ceftriaxone injection labels) for serious infections (hospital use). Class: cephalosporin antibiotic. Timing: once daily or as ordered. Purpose: treat severe bacterial infections. Mechanism: blocks bacterial cell wall synthesis. Side effects: diarrhea, biliary “sludge,” allergy risk. FDA Access Data+1

18. Oseltamivir (Tamiflu) for influenza (when started early and indicated). Class: antiviral neuraminidase inhibitor. Timing: twice daily for treatment courses. Purpose: shorten flu and reduce complications risk. Mechanism: blocks flu virus release from infected cells. Side effects: nausea/vomiting. FDA Access Data+1

19. Albuterol (inhalation solution or inhaler) for wheeze/bronchospasm (if present). Class: beta-2 agonist bronchodilator. Timing: as needed. Purpose: open airways and improve breathing. Mechanism: relaxes airway smooth muscle. Side effects: tremor, fast heartbeat. FDA Access Data+1

20. Hydrocortisone sodium succinate (Solu-Cortef) for emergency stress dosing in specific situations (only when a doctor diagnoses a need). Class: corticosteroid. Timing: emergency/short courses. Purpose: stabilize severe inflammation/shock states. Mechanism: replaces/boosts steroid effect and reduces inflammatory signals. Side effects: high sugar, infection risk if misused. FDA Access Data+1

Dietary molecular supplements

Safety note: Supplements can interact with medicines and can be unsafe in liver disease if taken in high doses. Use clinician-guided dosing. Office of Dietary Supplements+1

1. Vitamin D. Purpose: bone strength and immune support. Mechanism: helps calcium absorption and bone remodeling. Dose: follow age-based guidance and lab levels; avoid high doses long-term without monitoring. Office of Dietary Supplements+1

2. Calcium (diet first; supplement if needed). Purpose: bones/teeth and muscle function. Mechanism: structural mineral and nerve-muscle signaling. Dose: based on age intake goals and diet assessment. Office of Dietary Supplements+1

3. Omega-3 (DHA/EPA). Purpose: support brain, inflammation balance, and nutrition. Mechanism: membrane building blocks and signaling molecules. Dose: depends on product; food sources are preferred when safe. Office of Dietary Supplements+1

4. Zinc. Purpose: growth, wound healing, immune function. Mechanism: enzyme co-factor for many cell processes. Dose: age-based; too much zinc can cause harm and copper deficiency. Office of Dietary Supplements+1

5. Selenium. Purpose: antioxidant and thyroid support. Mechanism: part of selenoproteins that protect cells. Dose: age-based; excess selenium can be toxic. Office of Dietary Supplements+1

6. Folate (vitamin B9). Purpose: blood cells and growth. Mechanism: DNA synthesis support. Dose: guided by diet/labs; important if macrocytosis or deficiency is present. Office of Dietary Supplements+1

7. Vitamin B12. Purpose: nerves and blood cells. Mechanism: myelin and DNA pathways. Dose: based on labs; deficiency should be corrected medically. MDPI+1

8. Iron (only if deficiency confirmed). Purpose: prevent/treat anemia. Mechanism: hemoglobin oxygen transport. Dose: must be clinician-guided to avoid overload and stomach upset. MDPI+1

9. Coenzyme Q10 (CoQ10). Purpose: cellular energy support (some families try it for fatigue). Mechanism: mitochondrial electron transport role. Dose: product-dependent; evidence is mixed in rare disorders. ScienceOpen+1

10. Probiotic (strain-specific, cautious use). Purpose: gut comfort and stool regularity for some. Mechanism: may help gut microbiome balance. Dose: start low; avoid in severely immunocompromised patients unless a clinician approves. MDPI+1

Drugs/biologics sometimes used to “boost immunity” or support marrow/regeneration

These are not routine for every CDG-IIo patient. They are considered only when a doctor finds a clear indication (for example, proven antibody deficiency, severe recurrent infections, or low neutrophils due to another cause). Genetic Diseases Info Center+1

1. Immune globulin (IVIG; e.g., Gammagard). Purpose: replace missing antibodies. Mechanism: provides pooled IgG to help fight infections. Dose/timing: infusion schedule set by immunology. U.S. Food and Drug Administration+1

2. Filgrastim (Neupogen). Purpose: raise neutrophils when dangerously low. Mechanism: G-CSF stimulates bone marrow to make neutrophils. Dose/timing: weight-based and monitored by labs. FDA Access Data+1

3. Pegfilgrastim (Neulasta). Purpose: longer-acting neutrophil support in selected settings. Mechanism: long-acting G-CSF effect. Dose/timing: specialist-directed; not for routine use in children without a clear need. FDA Access Data+1

4. Sargramostim (Leukine). Purpose: stimulate broader white cell recovery in specific scenarios. Mechanism: GM-CSF supports myeloid cell growth. Dose/timing: specialist-only with monitoring. FDA Access Data

5. Palivizumab (Synagis; RSV prevention in high-risk infants) when a child meets criteria. Purpose: reduce severe RSV disease risk. Mechanism: antibody against RSV. Timing: monthly during RSV season for eligible infants. U.S. Food and Drug Administration+1

6. Somatropin (growth hormone) only if endocrinology confirms deficiency/indication. Purpose: improve growth and body composition. Mechanism: IGF-1 pathway stimulation. Timing: regular injections with growth monitoring. ScienceOpen+1

Surgeries/procedures

1. Gastrostomy tube (G-tube) placement. Why: long-term nutrition when swallowing is unsafe or calories are not enough. Helps growth and can reduce stress during feeding, though aspiration risk still needs careful management. MDPI+2PMC+2

2. Anti-reflux surgery (fundoplication) in selected cases. Why: severe reflux with aspiration, pain, or poor growth that does not improve with feeding plans and medicines. MDPI+1

3. Liver transplantation (only for advanced liver failure). Why: life-saving option when liver disease progresses despite best care. In CDG, transplant decisions are complex and done in expert centers. World CDG Organization+2PMC+2

4. Orthopedic surgery (contracture release/scoliosis surgery). Why: severe joint tightness or spine curvature that limits breathing, sitting, or care. Helps posture and comfort when therapy/orthotics are not enough. ScienceOpen+1

5. Airway procedures in severe aspiration/airway weakness (rare, specialist). Why: protect lungs when recurrent aspiration threatens life; the exact procedure depends on anatomy and swallow studies. Pediatrics+1

Preventions

1. Regular follow-ups and lab monitoring (liver enzymes, clotting, nutrition markers) to catch decline early. SpringerLink+1

2. Vaccinations on schedule and extra protection when doctors recommend it. Genetic Diseases Info Center+1

3. Prompt treatment of infections and clear “when to go to hospital” rules. Genetic Diseases Info Center+1

4. Aspiration prevention plan (swallow study, safe textures, positioning). MDPI+1

5. Nutrition plan to prevent malnutrition (calorie targets, tube feeding when needed). MDPI+1

6. Seizure action plan (rescue medicine rules, emergency contacts). FDA Access Data+1

7. Avoid unnecessary “megadose” supplements (especially fat-soluble vitamins) without lab guidance. Office of Dietary Supplements+1

8. Medication review at every visit to prevent harmful interactions and duplicate sedatives. FDA Access Data+1

9. Physical therapy and stretching routine to prevent contractures and pain. ScienceOpen+1

10. Family genetic counseling to prevent unexpected recurrence and plan future pregnancies safely. Genetic Diseases Info Center+1

When to see doctors urgently

Go for urgent medical care if there is trouble breathing, blue lips, repeated choking, signs of pneumonia (fast breathing, chest pulling in, high fever), seizure lasting longer than the rescue plan, severe sleepiness/hard to wake, dehydration (very low urine, sunken eyes), vomiting that will not stop, yellow skin/eyes getting worse, bleeding/bruising, or swollen belly with pain. These can signal serious infection, aspiration, liver decompensation, or uncontrolled seizures. Genetic Diseases Info Center+2Frontiers+2

What to eat and what to avoid

1. Eat: energy-dense meals (as advised), because some children burn energy fast or eat slowly. Avoid: “empty calorie” snacks that replace real nutrition. MDPI+1

2. Eat: enough protein (eggs, fish, meat, pulses) if tolerated. Avoid: very large protein loads without clinician advice in advanced liver failure. Frontiers+1

3. Eat: safe textures (puree/soft) if swallow is weak. Avoid: hard, dry, crumbly foods that increase choking. MDPI+1

4. Eat: small frequent meals if reflux is common. Avoid: lying flat right after eating. FDA Access Data+1

5. Eat: fluids as guided (oral or tube) to prevent constipation/dehydration. Avoid: dehydration, especially during fever/diarrhea. MDPI+1

6. Eat: fiber foods if safe to swallow (soft fruits/vegetables). Avoid: very high-fiber rough foods if they worsen bloating or swallowing safety. MDPI+1

7. Eat: foods rich in zinc/selenium (meat, fish, legumes, nuts) when age-appropriate. Avoid: high-dose zinc/selenium pills without lab/doctor guidance. Office of Dietary Supplements+1

8. Eat: calcium/vitamin D sources (milk/yogurt, fortified foods) if tolerated. Avoid: very high vitamin D dosing without monitoring. Office of Dietary Supplements+1

9. Eat: omega-3 sources (fish) if safe and culturally appropriate. Avoid: unverified “miracle cure” supplements sold online. Office of Dietary Supplements+1

10. Eat: medically prescribed formulas (oral or tube) if needed. Avoid: stopping formula or tube feeds suddenly without the care team. MDPI+1

FAQs

1. Is CDG-IIo the same as “CDG2O”? Yes, CDG-IIo is commonly described as CCDC115-CDG, also known as CDG2O. Genetic Diseases Info Center+1

2. Is it contagious? No. It is genetic, not an infection. Genetic Diseases Info Center

3. Did parents do something wrong? No. It usually happens because of inherited gene changes. Orpha+1

4. Can it be cured? There is no universal cure yet; care is supportive and organ-focused. ScienceOpen+1

5. Why is the liver often involved? Faulty glycosylation affects liver proteins and cell processing, and some CDG types cause progressive liver disease. Genetic Diseases Info Center+2PMC+2

6. Can seizures happen? Yes, seizures have been reported in CCDC115-CDG. Genetic Diseases Info Center+1

7. What test helps diagnosis? Doctors often use glycosylation screening (like transferrin patterns) plus genetic testing to confirm the gene. Cell+1

8. Is developmental delay common? Yes, global developmental delay is commonly described. Genetic Diseases Info Center+1

9. Will physiotherapy really help? It cannot fix the gene problem, but it can reduce stiffness, improve movement skills, and prevent complications. ScienceOpen+1

10. Are antibiotics taken every day? Usually no—only when a clinician diagnoses an infection or prevention is specifically indicated. FDA Access Data+1

11. Are supplements mandatory? Not always; they are used when diet is not enough or labs show deficiency, and dosing must be safe. Office of Dietary Supplements+1

12. Can a feeding tube be needed? Yes, if swallowing is unsafe or nutrition is not adequate, a G-tube can help long-term feeding. MDPI+1

13. Does a G-tube fully prevent pneumonia? Not always; aspiration can still occur, so feeding safety plans remain important. Pediatrics+1

14. Is liver transplant ever used in CDG? In selected CDG types (including CCDC115-CDG) transplantation has been reported/considered, but it must be decided by expert teams because CDG is multisystem. World CDG Organization+2PMC+2

15. What is the best next step after diagnosis? Build a care plan with genetics/metabolic, hepatology, neurology, nutrition, and therapies, and set clear emergency rules for seizures, infection, and liver warning signs. ScienceOpen+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 15, 2025.